Stephanie Clemens

Dr. Stephanie Clemens

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 December 2024 in Antioxidants
Verified
Journal Article
Open access
PDF file
OROlaf Rose
Olaf Rose
TCTim Croonenberg
Tim Croonenberg
SCStephanie Clemens
Stephanie Clemens
THTobias Hinteregger
Tobias Hinteregger
SEStefanie Eppacher
Stefanie Eppacher
Silvia DossenaSilvia Dossena
Silvia Dossena
Cisplatin is an established component of treatment protocols for various solid malignancies but carries a significant potential for serious adverse effects. Ototoxicity from cisplatin treatment is an important dose-limiting toxicity that manifests as bilateral, progressive, irreversible, dose-dependent sensorineural hearing loss, ear pain, tinnitus, and vestibular dysfunction. Despite the recent approval of sodium thiosulphate for the prevention of cisplatin-induced hearing loss (CIHL) in pediatric patients, structured prevention programs are not routinely implemented in most hospitals, and reducing platinum-induced ototoxicity in adults remains an important clinical problem without established treatment options. Cochlear oxidative stress plays a fundamental role in CIHL. Here, we review the molecular mechanisms leading to oxidative stress in CIHL and the clinical and preclinical studies testing antioxidants in CIHL to guide future clinical trials in assessing the efficacy and safety of candidate antioxidant compounds in this clinical setting.

11 October 2024 in Biomedicines
Verified
Journal Article
Open access
PDF file
OROlaf Rose
Olaf Rose
SHSophia Marie Huber
Sophia Marie Huber
ETEugen Trinka
Eugen Trinka
JPJohanna Pachmayr
Johanna Pachmayr
SCStephanie Clemens
Stephanie Clemens
Objectives: Parkinson’s disease psychosis (PDP) is a prevalent non-motor symptom associated with Parkinson’s disease. The treatment options for PDP are limited, and its pharmacological management remains ambiguous. This study aimed to evaluate the existing evidence in relation to clinical practice. Methods: This multi-methods study consisted of a systematic review of reviews, adhering to the PRISMA guidelines. The review was registered with PROSPERO. Following data extraction and assessment using the AMSTAR 2 tool, a narrative synthesis was performed. In the second phase of the study, a questionnaire was developed, validated, piloted, and distributed to the heads of specialized PD clinics in Germany and Austria. Results: The search resulted in the inclusion of eleven reviews. The quality of eight of these reviews was rated as high (n = 7) or moderate (n = 1). The reviews indicated that clozapine and pimavanserin demonstrated the highest efficacy and tolerability. Other antipsychotic medications either failed to alleviate PDP symptoms or resulted in distinct motor complications. The survey findings also favored clozapine for its efficacy in managing PDP and improving quality of life, although quetiapine was regarded as effective and pimavanserin was not available. Clinicians reported initiating antipsychotic treatment at various stages of PDP, with a tendency to reduce the dosage or discontinue D2 agonists or anticholinergics. Conclusions: The reviewed literature and the survey results consistently favored clozapine for its efficacy and tolerability in treating PDP. It may be considered the first-line treatment, with pimavanserin as an alternative option.

8 September 2025 in Pharmacy
Verified
Journal Article
Open access
PDF file
OROlaf Rose
Olaf Rose
CEClarissa Egel
Clarissa Egel
JPJohanna Pachmayr
Johanna Pachmayr
SCStephanie Clemens
Stephanie Clemens
In Austria, community pharmacists may dispense prescription-only drugs in exceptional emergency cases. Hospital pharmacists are permitted to adapt or discontinue therapy with prior physician approval. This mixed-methods study explores how Austrian pharmacists interpret and apply these frameworks, their readiness for expanded roles, and the systemic conditions required to support broader clinical engagement. A cross-sectional design was used with two online surveys targeting community and hospital pharmacists. Additionally, 15 semi-structured interviews were conducted (ten community, five hospital pharmacists). Quantitative data were analyzed descriptively; qualitative data were examined using Mayring’s content analysis. Data integration followed a triangulation design via mixed-methods matrices. A total of 238 community and 53 hospital pharmacists responded. Findings show that community pharmacists frequently apply clinical judgment in urgent situations and navigate regulatory grey zones. Over 88% support expanded roles, particularly in continuing contraceptives, managing chronic diseases, and treating infections using point-of-care testing. Hospital pharmacists report limited implementation of their framework, hindered by institutional inertia, staffing shortages, and poor access to patient data. Confidence in clinical pharmacotherapy decisions was limited. Targeted training and policy support are essential.

1 November 2025 in Pharmacy
Verified
Journal Article
Open access
PDF file
SCStephanie Clemens
Stephanie Clemens
LELea Eisl-Raudaschl
Lea Eisl-Raudaschl
JPJohanna Pachmayr
Johanna Pachmayr
OROlaf Rose
Olaf Rose
Increasing healthcare demands and physician shortages have prompted many countries to expand clinical responsibilities of pharmacists. Although Canada, the UK, and the US have implemented pharmacist prescribing, other nations lag behind. This review compares international roles, identifies inferred competencies, and explores implications for role expansion. A systematic search of MEDLINE, CINAHL, and the Cochrane Library was conducted using the PICO framework; studies were appraised with Critical Appraisal Skills Programme (CASP) checklists, and interrater reliability assessed via Cohen’s Kappa. Data from 23 studies were thematically synthesized following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines. Four themes emerged: (1) expanding clinical and public health roles and pharmacists’ self-perceived readiness; (2) regulatory frameworks defining legal authority, qualifications, and temporary pandemic exemptions; (3) inferred competencies, including micro-skills (patient assessment, guideline application) and macro-capabilities (clinical judgment, accountability, reflective practice); and (4) contextual barriers such as training gaps, limited funding, unclear legal provisions, and workflow challenges. Implementation implications were synthesized and included training, funding, acceptance, and integration. Evidence indicates pharmacist prescribing is safe and patient-centered when supported by regulation, structured training, and systemic integration. Insights from established models can guide incremental implementation, optimizing medication management, enhancing healthcare access, and promoting equitable care.

23 September 2025 in Journal of Pharmaceutical Policy and Practice
Verified
Journal Article
Open access
OROlaf Rose
Olaf Rose
KHKreshnik Hoti
Kreshnik Hoti
BIBlete Isufi
Blete Isufi
MWMatthias Wachinger
Matthias Wachinger
JPJohanna Pachmayr
Johanna Pachmayr
SCStephanie Clemens
Stephanie Clemens
As the prevalence of drug shortages has markedly escalated in recent years, this study seeks to investigate the associated clinical implications and burdens in Austria, Germany and Kosovo where healthcare systems differ significantly. The research was conducted as a trinational, multiple-methods study utilising questionnaires and in-depth interviews for different stakeholders, including patients, physicians, pharmacists and manufacturers. Descriptive statistics were applied to summarise and analyse the quantitative dataset, providing key insights into central tendencies and overall data distribution, while qualitative data were analysed using the summarising approach based on Mayring’s qualitative content analysis. Manufacturers expressed concerns regarding the intense pressure on pricing amid global inflation. Proposed mitigation strategies were anticipated to incur higher costs, with increased stockpiling in one major country adversely affecting others. Pharmacists across all three nations reported significant disruptions to their clinical practice, with up to fifty per cent of patient encounters being affected by drug shortages, requiring considerable amounts of time to resolve. They expressed feelings of frustration and anger, citing bureaucratic obstacles and excessive regulation as impediments to effective problem-solving. Physicians reported similar challenges in their practice, often resorting to self-initiated solutions and advocating for improved information regarding drug availability. While most patients have been exposed to drug shortages, the majority of these issues were resolved with moderate interruptions to their therapy. The root causes of these problems were primarily attributed to political factors. The results show that drug shortages have significantly disrupted clinical practice across all three countries, with pharmacists and physicians reporting major impacts on patient care and increased time spent resolving issues. Economic pressures, political factors and regulatory obstacles were identified as key causes exacerbating the crisis and highlighting the need for coordinated mitigation strategies.

13 February 2026 in International Journal of Pharmacy Practice
Verified
Journal Article
Open access
OROlaf Rose
Olaf Rose
JPJohanna Pachmayr
Johanna Pachmayr
SCStephanie Clemens
Stephanie Clemens
Clinical pharmacy and pharmacy practice research in Austria has evolved more slowly than in some other countries, but recent years have seen notable progress. Geographic disparities still limit access in certain regions, yet policymakers increasingly acknowledge the essential role of pharmacies, while remaining focused on cost containment. Curricula at universities vary, with most universities still focussing on pharmaceutical chemistry and traditional content and one university teaching pharmacotherapy and medication review to a higher extent. The switch to the bachelor’s and master’s degree system has increased research involvement, as all pharmacy students must complete two original research projects for their theses. These projects often interact with pharmacy practice. Various postgraduate pathways support continued involvement in research. Fostered by the theses, pharmacy education develops research competence across the entire cohort rather than limiting it to a small academic subset. However, maintaining research engagement after graduation remains difficult. Once pharmacists enter practice, particularly in community settings, limited institutional links, lack of protected time, and scarce funding opportunities tend to interrupt this trajectory. A few postgraduate programs provide structured pathways to continue academic or clinical research, yet participation is optional and dependent on individual motivation. Strengthening continuity between academic training and professional environments would help consolidate the existing research competencies and foster a more sustainable research culture within the profession. The recently introduced mandatory system of continuing professional education further supports this development by bringing academia and practitioners closer together and by promoting a culture of shared learning and ongoing inquiry. Although the number of clinical pharmacists remains relatively low, their presence on hospital wards is expanding and increasingly valued, while community pharmacies are also beginning to offer clinical pharmacy services. Strengthening Austria’s pharmacy profession requires closer alignment between educational reform, professional practice, and health policy. Policymakers should make more systematic use of pharmacists’ competencies as accessible first points of contact within primary care. Expanding their scope to include structured involvement in the pharmacotherapy of prevalent chronic diseases such as atherosclerosis, diabetes, and hypertension, as well as in screening and prevention programs, would not only improve population health but also bring translational research closer to everyday pharmacy practice. Evidence demonstrates that Austrian pharmacists are well prepared for expanded clinical responsibilities and show high professional motivation to assume such roles. These developments should be accompanied by targeted curricular reforms that strengthen clinical reasoning, interprofessional collaboration, and applied research competencies. International collaboration and participation in European research and education networks can further enhance Austria’s research capacity and harmonize national progress with global best practices. By bridging policy, education, and professional development, pharmacists can evolve from their current multifaceted roles into active contributors to patient-centred research and evidence-based healthcare, while remaining closely connected to continuous education and research.